The European Patent Office published patent application EP4232449A1 for Celgene Corporation and Zoetis LLC, covering heterocyclic compounds and their use for treating helminthic infections and diseases, published April 15, 2026. The compounds carry multiple IPC classifications including C07D 417/14, C07D 413/14, C07D 401/14, C07D 471/04, C07D 491/048, and are designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, SE. The publication establishes priority rights and enables public inspection of the specific heterocyclic compound compositions and therapeutic uses disclosed in the application.
